��������

Maritza McIntyre, PhD, has 20 years of experience in the development, evaluation and regulation of biological and small molecule products within startup biotech firms, the Food and Drug Administration (FDA), and as a consultant.

Dr. McIntyre was a product reviewer and ultimately Branch Chief in the Division of Cellular and Gene Therapies at FDA/CBER. She has since worked in senior roles in regulatory affairs and product development at Bavarian Nordic, REGENXBIO, NanoCor Therapeutics and Bamboo Therapeutics. As president of Advanced Therapies Partners, Dr. McIntyre provides strategic regulatory and product development advice to biotech companies, academics, and venture capital firms. She has proven success in defining development strategies for products with complex regulatory challenges. She has also been involved in the preparation of some of the first BLA and MAA submissions for gene therapy products to FDA and EMA.

Dr. McIntyre received a Ph.D. in virology from the University of Chicago and graduated magna cum laude with an Honors B.S. in biology from Wayne State University.